Cargando…
Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial—the ‘DEXAPAE’ study
INTRODUCTION: Postembolisation syndrome (PES) is the most common side effect of vascular embolisation of solid organs. Although prophylactic corticosteroids are known to reduce the incidence and severity of PES, no trials investigating their efficacy have been conducted in men undergoing prostatic a...
Autores principales: | Svarc, Petra, Stroomberg, Hein Vincent, Juhl Jensen, Ruben, Frevert, Susanne, Håkan Lindh, Mats, Taudorf, Mikkel, Brasso, Klaus, Lönn, Lars, Røder, Martin Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562514/ https://www.ncbi.nlm.nih.gov/pubmed/34725072 http://dx.doi.org/10.1136/bmjopen-2020-047878 |
Ejemplares similares
-
Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review
por: Svarc, Petra, et al.
Publicado: (2020) -
Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery
por: Malling, Brian, et al.
Publicado: (2019) -
Danish Prostate Registry (DanProst) – an Updated Version of the Danish Prostate Cancer Registry, Methodology, and Early Results
por: Stroomberg, Hein Vincent, et al.
Publicado: (2023) -
Prostatic Artery Embolization for the Treatment of Benign Prostate Hyperplasia: Initial Experience From Bahrain
por: Hamed Ibrahim, Wael, et al.
Publicado: (2022) -
Risk of prostate cancer and death after benign transurethral resection of the prostate—A 20‐year population‐based analysis
por: Hilscher, Maria, et al.
Publicado: (2022)